Trial Profile
Incidence and predictive factors of symptom recurrence after discontinuation of successful mirabegron therapy in patients with overactive bladder.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2017
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 29 Nov 2017 New trial record